US 11,052,069 B2
Regimes of FXR agonists
Bryan Laffitte, Cardiff, CA (US); Andreas Bauer, Basel (CH); Michael Badman, Newton, MA (US); Jin Chen, Randolph, NJ (US); Patrick Mueller, Bottmingen (CH); and Rachel Soon, Budd Lake, NJ (US)
Assigned to Novartis AG, Basel (CH)
Appl. No. 16/333,030
Filed by NOVARTIS AG, Basel (CH)
PCT Filed Sep. 12, 2017, PCT No. PCT/IB2017/055501
§ 371(c)(1), (2) Date Mar. 13, 2019,
PCT Pub. No. WO2018/051229, PCT Pub. Date Mar. 22, 2018.
Claims priority of provisional application 62/425,179, filed on Nov. 22, 2016.
Claims priority of provisional application 62/394,463, filed on Sep. 14, 2016.
Prior Publication US 2019/0262313 A1, Aug. 29, 2019
Int. Cl. A61K 31/4162 (2006.01); A61K 31/4178 (2006.01); A61P 1/16 (2006.01); A61K 9/00 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4162 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4178 (2013.01); A61K 31/55 (2013.01); A61P 1/16 (2018.01); A61K 45/06 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method for treating diabetic nephropathy in a human, comprising administering to a human in need thereof, a daily dose of about 50 mg to about 200 mg of 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.